[单克隆抗体KM10与抗癌胚抗原单克隆抗体的比较研究]

[Comparative studies on monoclonal antibody KM10 and anti-CEA monoclonal antibodies].

作者信息

Soyama N, Yamamoto M, Ohyanagi H, Saitoh Y

机构信息

First Department of Surgery, Kobe University, School of Medicine, Japan.

出版信息

Nihon Geka Gakkai Zasshi. 1989 Nov;90(11):1834-9.

PMID:2481805

Abstract

The specificity of KM10 was evaluated in comparison with newly developed anti-CEA monoclonal antibodies (A10, B9, JA4, AH3). Both KM10 and all anti-CEA monoclonal antibodies reacted with CEA in ELISA system, and with adenocarcinoma of the stomach, colon, and pancreas in the immunohistochemical assay. B9, JA4, and AH3 were suggested to react with CEA related antigens, such as NCA and BGPI, whereas KM10 and A10 were suggested to recognize the distinctive part of CEA. The antigenic determinant of CEA reactive with KM10 and A10 was revealed to be protein moiety after enzyme treatment. The competitive binding inhibition assay, however, indicated that epitopes of KM10 and A10 were different each other. Enzyme immunoassay using both KM10 and A10 could detect CEA. These findings showed the possible use of both KM10 and A10 for clinical diagnosis and treatment by means of targeting for the distinctive part of CEA.

摘要

与新开发的抗癌胚抗原（CEA）单克隆抗体（A10、B9、JA4、AH3）相比，对KM10的特异性进行了评估。在酶联免疫吸附测定（ELISA）系统中，KM10和所有抗CEA单克隆抗体均与CEA发生反应，在免疫组织化学检测中，它们与胃、结肠和胰腺的腺癌也发生反应。有人认为B9、JA4和AH3与CEA相关抗原如NCA和BGPI发生反应，而KM10和A10则被认为识别CEA的独特部分。酶处理后发现，与KM10和A10发生反应的CEA的抗原决定簇是蛋白质部分。然而，竞争性结合抑制试验表明，KM10和A10的表位彼此不同。使用KM10和A10的酶免疫测定均可检测CEA。这些发现表明，KM10和A10通过靶向CEA的独特部分，有可能用于临床诊断和治疗。